Abliva AB represents values of innovation, integrity, and commitment to improving patients' lives. With a corporate philosophy centered around scientific excellence, Abliva aims to develop effective treatments for rare mitochondrial disorders and other genetic diseases. By harnessing its expertise in mitochondrial medicine and drug development, the company strives to bring forth novel therapies that address unmet medical needs. Abliva AB's dedication to collaboration and cutting-edge research further fuels its mission, enabling the advancement of potential breakthrough treatments. Through its focus on improving patient outcomes and pushing the boundaries of medical innovation, Abliva AB demonstrates a strong commitment to making a positive impact in the field of medicine.

Abliva AB is primarily present in Sweden, with its headquarters located in Stockholm. As a biopharmaceutical company, Abliva AB focuses on the research and development of treatments for rare mitochondrial diseases. With a strong presence in the Swedish healthcare industry, Abliva AB aims to improve the quality of life for patients suffering from these conditions.

Abliva AB has achieved several significant milestones in its journey. Notable achievements include the successful completion of Phase IIa clinical trial of KL1333, a potential treatment for mitochondrial diseases. The company also received Orphan Drug Designation for KL1333 from the U.S. FDA and the European Medicines Agency, recognizing its potential in addressing unmet medical needs. Furthermore, Abliva AB has forged collaborative partnerships with renowned institutions like Massachusetts General Hospital and The Feinstein Institutes for Medical Research, enhancing its research and development capabilities. These milestones demonstrate Abliva AB's commitment to advancing breakthrough therapies for mitochondrial disorders and underline its position as a leading player in the field.

Abliva AB is a biopharmaceutical company based in Sweden. It was founded in 2016 and is focused on developing treatments for rare mitochondrial diseases. The company's mission is to improve the lives of patients with these challenging conditions by advancing innovative therapies. Abliva AB combines cutting-edge science with a deep understanding of mitochondrial biology to identify potential drug candidates. With a dedicated team of experts, Abliva AB continues to research and develop promising treatments to address unmet medical needs in the field of mitochondrial diseases. Abliva AB is committed to making a positive impact on patients' lives and transforming the landscape of mitochondrial medicine.

Abliva AB faces competition from various companies in the market, including XYZ Corporation, ABC Inc., and DEF Ltd.

Abliva AB is primarily active in the pharmaceutical and biotechnology industries.

The business model of Abliva AB is focused on the development and commercialization of innovative treatments for rare mitochondrial diseases. Abliva AB aims to address the unmet medical needs of patients by developing effective therapies that target the underlying causes of these debilitating conditions. The company's business strategy revolves around identifying potential drug candidates, conducting preclinical and clinical studies, seeking regulatory approvals, and ultimately bringing its products to market. By leveraging its expertise in mitochondrial medicine, Abliva AB aims to improve the lives of patients affected by rare mitochondrial diseases through the development of novel and targeted therapies.

Det Abliva P/E-forhold er -1,24.

Abliva KUV er 0.

AlleAktien Kvalitetsscore for Abliva er 2/10.

Omsætningen kan i øjeblikket ikke beregnes for Abliva.

Den forventede Abliva indtjening er -131,53 mio. SEK.

Abliva AB is a biopharmaceutical company based in Stockholm, Sweden. The company specializes in the development of therapeutics for the treatment of rare diseases. Abliva AB has three main business areas: Neurology, Mitochondrial Diseases, and other rare diseases. The company has several product candidates in the pipeline targeting various disease areas. One of Abliva AB's key product candidates is KL1333, an oral medication for the treatment of primary mitochondrial myopathy (PMM). PMM is a rare disease that affects muscle function and typically occurs early in life. KL1333 is currently in Phase IIb clinical trials and has the potential to be an important treatment option for patients with PMM. Another important product candidate of Abliva AB is NV354, an oral medication for the treatment of epilepsy and other neurological disorders. NV354 is currently in the preclinical phase and shows promising results in animal models. Abliva AB is also working on developing therapeutics for the treatment of other rare diseases such as liver diseases and metabolic disorders. The company has a strong pipeline of product candidates expected to be brought to market in the coming years. Abliva AB's business model is based on partnerships with other pharmaceutical companies and investors to finance and accelerate the development of its product candidates. Abliva AB collaborates closely with leading scientists and researchers to develop innovative therapeutics for the treatment of rare diseases. Abliva AB also has strong intellectual property and patents its technologies and product candidates, which helps strengthen its competitive position and ensure the protection of its products in the market. Overall, Abliva AB aims to play a significant role in the development of therapeutics for the treatment of rare diseases. The company has a strong pipeline of product candidates and works closely with other companies and investors to finance and advance the development of its products. With its strong intellectual property and innovative research, Abliva AB has the potential to play a key role in the treatment of rare diseases and improve the lives of affected patients.

Abliva udbetaler et udbytte på 0 SEK fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Abliva, eller selskabet udbetaler ikke udbytte.

ISIN'en for Abliva er SE0002575340.

WKN for Abliva er A0X93Z.

Tickeren for Abliva er ABLI.ST.

I løbet af de sidste 12 måneder betalte Abliva en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Abliva sandsynligvis betale en dividende på 0 SEK.

Udbytteafkastet for Abliva er i øjeblikket .

Abliva betaler kvartalsvis udbytte. Dette uddeles i månederne .

Abliva betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 SEK. Dette svarer til et dividendeafkast på 0 %.

Abliva bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Abliva fra den 21.10.2024 på 0 SEK, skulle du have haft aktien i din portefølje før ex-datoen den 21.10.2024.

Udbetalingen af det sidste udbytte blev foretaget den 21.10.2024.

I løbet af 2023 udbetalte Abliva 0 SEK i form af dividender.

Udbytterne fra Abliva udbetales i SEK.